R&D-Intensity Value
In plain terms
Standard value factors mistake R&D-heavy tech firms as 'growth' because R&D is expensed not capitalized. Adding R&D back uncovers hidden value.
How it works
Standard book-to-market based value factors mis-classify R&D-heavy firms as "growth" because R&D is expensed (not capitalized) under GAAP. Peters-Taylor 2017 + Eisfeldt-Kim-Papanikolaou 2020 show that adding capitalized R&D back to book equity restores the value premium for tech/biotech and reverses the apparent "value-is-dead" finding of the 2010s. We compute an R&D-intensity metric per ticker and overweight it when it's accompanied by a price drawdown — the intangibles-implied value play.
Live results
0 times picked on its own · 3 times inside a blend (3 beat the stock) · updated 2026-06-06Data dependencies
- Daily prices
Adjusted-close OHLCV for every US-listed ticker; primary price feed.
- Fundamentals
Quarterly fundamentals (income, balance, cash-flow) from FMP + SEC.
Expected edge
- Tested over
- 1975-2005 (Lev-Sougiannis)
See the source research for the original effect size; a modern replication on new data may be weaker.
Explore R&D-Intensity Value on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.